Tesamorelin Study Duration, Endpoints, and Reported Outcomes

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes the durations, prespecified endpoints, and reported outcomes for tesamorelin in the reviewed literature, focusing on human clinical trial data and its regulatory context. The primary human trial excerpted here is a 6-month Phase II randomized open-label study in virally suppressed people with HIV and abdominal obesity; additional sources describe tesamorelin’s approved indication and its place among growth-hormone–releasing agents in the literature.

Primary human clinical trial evidence (Phase II randomized trial)

A multicenter Phase II randomized open-label clinical trial reported a 6-month comparison of tesamorelin versus standard of care in virally suppressed people with HIV and abdominal obesity; 73 participants were randomized in a 3:2 ratio to tesamorelin or standard of care (SOC) (primary outcome: change in neurocognitive performance at 6 months). ^[S6]

The tesamorelin regimen in this trial was reported as 2 mg administered subcutaneously daily, and the study evaluated neurocognitive performance as the primary endpoint with secondary outcomes including waist circumference (WC), mood, and daily functioning. ^[S6]

Reported study durations and endpoints across reviewed sources

Among the reviewed human data, the explicit trial duration reported is 6 months; narrative reviews of peptide therapies note that information regarding dosing, frequency, and duration is often incomplete or lacking for many peptide applications, and that clinical evidence outside approved indications is limited. ^{[S6] [S2]}

Outcomes reported in the Phase II trial (efficacy and biomarkers)

Neurocognitive performance: the tesamorelin group showed a trend toward improved neurocognitive performance after 6 months (mean change, 0.146; 95% CI, -0.002 to 0.294; P = .060), whereas the SOC group did not (mean change, 0.103; 95% CI, -0.095 to 0.301; P = .295), and the between-group difference was not statistically significant (P = .673). ^[S6]

Waist circumference and biomarker changes: tesamorelin recipients had a greater reduction in waist circumference than the SOC group (median difference, -2.7 cm; P = .015). IGF-1 levels increased in the tesamorelin group, but reported changes in IGF-1 did not correlate with the summary regression change score for neurocognitive performance or with WC in the trial report. ^[S6]

Regulatory status and broader evidence context

Tesamorelin (Egrifta) is an approved growth hormone–releasing factor analogue for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; narrative reviews place tesamorelin among growth hormone secretagogues that increase IGF-1 signaling. Reviews of peptide therapies emphasize a limited clinical trial base for many proposed indications beyond the approved metabolic indication and note a lack of orthopaedic evidence for tesamorelin specifically. ^{[S4] [S3] [S1] [S2]}

Study design limitations explicitly reported in the trial

The Phase II trial authors noted limitations including insufficient power to detect small neurocognitive effects and the absence of a placebo arm (the trial was open-label), which constrain causal interpretation of cognitive outcome differences between arms. ^[S6]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• The human trial evidence in the reviewed sources is limited to a single Phase II randomized open-label study for neurocognitive outcomes; broader claims about tesamorelin’s effects outside the reported endpoints are not supported by the provided excerpts.
• Several reviewed items are narrative reviews that note an overall paucity of clinical trials for many peptide claims; this restricts the ability to generalize trial findings to other populations or indications.
• Key trial features that affect interpretation were present (open-label design, lack of placebo, modest sample size and power); these limit confidence in small or non-significant between-group differences.
• The reviewed sources do not provide additional randomized, placebo-controlled, or longer-duration trial data for the outcomes summarized here.

Documentation checklist

• Confirm the trial population (virally suppressed people with HIV and abdominal obesity) in source documents before interpreting outcomes.
• Verify primary and secondary endpoints and their prespecified timepoints in the original study record.
• Note study design features that affect interpretation: randomization ratio, blinding status, presence/absence of placebo, and sample size/power.
• Cross-check reported outcome statistics (point estimates, confidence intervals, P values) against the primary source.
• When comparing endpoints across sources, separate peer-reviewed trial data from narrative review statements.

Related research supplies

• Temperature-controlled storage logs and refrigerator/freezer monitoring for investigational peptide products
• Assay kits and laboratory documentation for measuring serum IGF-1
• Standardized anthropometry tools and documentation (waist circumference measuring tape, protocol sheets)
• Case report forms and validated neurocognitive test battery documentation
• Electronic data capture and inventory management software for trial drug accountability

Sources and references

1. [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
2. [S2] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
3. [S3] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
4. [S4] Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin.. Nature reviews. Drug discovery. 2011. PMID: 21283099. DOI: 10.1038/nrd3362
5. [S5] Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.. International journal of molecular sciences. 2026. PMID: 42123471. DOI: 10.3390/ijms27093890
6. [S6] Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.. The Journal of infectious diseases. 2025. PMID: 39813152. DOI: 10.1093/infdis/jiaf012

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.